FDA held a Listening Session with Inclusion Body Myositis (IBM) patients and care partners on March 5, 2020. Patient Listening Sessions are intended to be a resource for the FDA’s medical product centers to engage with patients and their advocates. The IBM session was patient-led, meaning that The Myositis Association (TMA) requested and received the opportunity to share its members’ perspectives with the FDA. Click here to find the summary report of this meeting.